Abstract
Andrew S. Guinigundo, MSN, RN, CNP, ANP-BC, of Cincinnati Cancer Advisors, discusses the effect of Medicaid expansion on racial disparities in mortality among patients with gastrointestinal malignancies. He also describes the phase III DUO-O trial, which evaluated therapies for patients with advanced ovarian cancer without a BRCA1/2 mutation. Finally, the first tumor-agnostic global study of fam-trastuzumab deruxtecan-nxki showed encouraging results in patients with different cancers.
